Skip to content

Biohaven BHVN Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss?
Biohaven (BHVN) reported debt securities, available-for-sale, amortized cost, after allowance for credit loss of $150.53M in Q1 2026.
How has Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss changed year-over-year?
Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss decreased by 32.9% year-over-year, from $224.29M to $150.53M.
What is the long-term trend for Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss?
Over 3 years (2022 to 2025), Biohaven's debt securities, available-for-sale, amortized cost, after allowance for credit loss has grown at a -28.4% compound annual growth rate (CAGR), from $310.51M to $114.11M.